Estrone

Mechanism-of-action class: Estrogen Receptor Agonists.

• Discomfort and aches associated with PMS*

Adults and children: At the onset of symptoms, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a doctor.

1. 1Fatigue149.7%
2. 2Nausea117.6%
3. 3Decreased Appetite106.9%
4. 4Diarrhoea106.9%
5. 5Breast Cancer Female96.2%
6. 6Weight Increased96.2%
7. 7Arthralgia85.5%
8. 8Condition Aggravated85.5%
9. 9Off Label Use85.5%
10. 10Vomiting85.5%
11. 11Dyspnoea74.8%
12. 12Fall74.8%
13. 13Pain74.8%
14. 14Asthenia64.1%
15. 15Breast Cancer64.1%

Recent PubMed references pinned to Estrone as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Synthesis and Characterization of Chemically Stable N7-dG Estrone and Catechol Adducts.
  Molecules (Basel, Switzerland) · 2026 · Baily PT, Lee S
  PMID 42197187DOI 10.3390/molecules31101632
• Estrobolome: Is there a missing link?
  The Journal of steroid biochemistry and molecular biology · 2026 · Benagiano G, Pluchino N, Archer DF, et al.
  PMID 41707838DOI 10.1016/j.jsbmb.2026.106967
• Estrone-α-2-Deoxy-Glucoside as a Targeted Therapy for Triple-Negative Breast Cancer: Aromatase Inhibition and Cytotoxicity.
  Chemical biology & drug design · 2026 · Huang TY, Wang MR, Chou FP, et al.
  PMID 41614640DOI 10.1111/cbdd.70251
• Estrone Linked BODIPYs: Assessing Their Role as Sonosensitizers for Antimicrobial Applications.
  Chemistry, an Asian journal · 2026 · Siwach A, Shukla H, Jain A, et al.
  PMID 41603555DOI 10.1002/asia.70584
• Estrone exposure-induced feminization in male Siniperca chuatsi: A multidimensional study on sex reversal, liver damage, and changes in gene expression.
  Comparative biochemistry and physiology. Part D, Genomics & proteomics · 2026 · Chen K, Li W, Chen W, et al.
  PMID 41349460DOI 10.1016/j.cbd.2025.101705
• Stoichiometric transport of estrone 3-sulfate among genetic variants of OATP1A2 and OATP2B1 and structural analysis by molecular dynamics simulation: Impairment of gating mechanism in the unstable inward-open conformation of OATP2B1 (Asp215Val) significantly suppress the transport activity.
  Drug metabolism and disposition: the biological fate of chemicals · 2025 · Akiyoshi T, Tonduru AK, Kataoka H, et al.
  PMID 41349357DOI 10.1016/j.dmd.2025.100198
• MicroRNA mediated downregulation of HSD17B1 impairs estrone-to-estradiol conversion in polycystic ovarian syndrome.
  Reproductive biology · 2025 · Bhandary P, Shetty PK, Shetty P, et al.
  PMID 41027258DOI 10.1016/j.repbio.2025.101085
• Multifunctional Estrone-Polyoxometalate-F16 Hybrid Conjugate: A Synergistic Targeting Approach against Breast Cancer Cells.
  ACS applied bio materials · 2025 · Ahmadi M, Sadeghi F, Soltanabadi A, et al.
  PMID 40999740DOI 10.1021/acsabm.5c01114

The 10 most recently updated of 248 ClinicalTrials.gov registrations naming Estrone as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
  Recruiting · Phase 1 · Interventional · 24 enrolled · Deciphera Pharmaceuticals, LLC
  NCT07539090updated 2026-06-05
• A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
  Recruiting · Phase 1 · Interventional · 50 enrolled · AstraZeneca
  NCT07013643updated 2026-05-11
• A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
  Recruiting · Phase 1 · Interventional · 16 enrolled · AbbVie
  NCT07502417updated 2026-04-28
• A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
  Active not recruiting · Phase 1 · Interventional · 20 enrolled · AbbVie
  NCT07414784updated 2026-04-27
• A Study of Elenestinib in Healthy Adult Female Participants
  Completed · Phase 1 · Interventional · 20 enrolled · Blueprint Medicines Corporation
  NCT07388511updated 2026-04-20
• NATural Ovarian Stimulation
  Completed · Phase 4 · Interventional · 129 enrolled · Assistance Publique - Hôpitaux de Paris
  NCT02892942updated 2026-04-03
• A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
  Not yet recruiting · Phase 1 · Interventional · 24 enrolled · Novartis Pharmaceuticals
  NCT07340190updated 2026-04-02
• An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin
  Completed · Phase 1 · Interventional · 24 enrolled · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
  NCT07269327updated 2026-03-18
• A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause
  Completed · Phase 1 · Interventional · 47 enrolled · Novo Nordisk A/S
  NCT06513104updated 2026-03-12
• Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring
  Completed · Phase 3 · Interventional · 1,200 enrolled · Premier Research
  NCT00455156updated 2026-01-23

Frequently asked questions

How does Estrone work?

Mechanism-of-action class: Estrogen Receptor Agonists.

What is Estrone used for?

According to FDA labeling, Estrone carries indications including: Discomfort and aches associated with PMS*. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Estrone?

Estrone is classified as Estrogens, combinations with other drugs, Natural and semisynthetic estrogens, plain, Estrogen Receptor Agonists, Bone Formation Stimulation, Decreased Follicle Stimulating Hormone Secretion, Decreased Luteinizing Hormone Secretion, Hematologic Activity Alteration, Vaginal Function Alteration.